Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

Background: Development of novel agents targeting the androgen axis has led to improved overall survival in castration-resistant prostate cancer (CRPC). This study aimed to investigate the optimal timing of treatment with one such agent, abiraterone acetate (AA), in Japanese patients. Materials and...

Full description

Bibliographic Details
Main Authors: Takashi Nagai, Taku Naiki, Keitaro Iida, Toshiki Etani, Ryosuke Ando, Shuzo Hamamoto, Yosuke Sugiyama, Hidetoshi Akita, Hiroki Kubota, Yoshihiro Hashimoto, Noriyasu Kawai, Takahiro Yasui
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Prostate International
Subjects:
abiraterone acetate
castration-resistant prostate cancer
combined androgen blockade
Online Access:http://www.sciencedirect.com/science/article/pii/S2287888217300211

Internet

http://www.sciencedirect.com/science/article/pii/S2287888217300211

Similar Items